#300 - Who Should Take GLP-1s? The Science of Obesity, Appetite & Weight Loss | Dr. Robert Kushner & Mike Haney
LEVELS – A Whole New LevelShow Notes
What are GLP-1 drugs actually doing in the body, who are they for, and why might some people want to think twice before treating them like a six-month shortcut? For years, obesity treatment focused largely on behavior: eat less, move more, stay motivated. Yet many people lost weight only to regain it. According to obesity medicine pioneer Dr. Robert Kushner, that wasn’t a failure of willpower. It was a failure to fully understand the biology driving weight regulation. In this episode of A Whole New Level, Mike Haney sits down with Kushner, one of the leading figures in obesity medicine and a lead investigator on the landmark STEP trials, to discuss how GLP-1 medications are changing the field. He explains why these drugs may be the first treatments capable of helping patients “fight biology with biology,” why appetite regulation appears to work differently in different people, and why many patients describe a dramatic reduction in food noise after starting treatment. But this conversation goes beyond how the drugs work. Kushner also addresses one of the biggest questions facing obesity medicine today: who should actually take these medications? He explains why obesity specialists evaluate far more than a number on the scale, why someone hoping to lose a modest amount of weight may want to think carefully before pursuing treatment, and why successful long-term health still requires changes that no medication can provide. They also discuss obesity as a disease, the promise and limitations of telehealth prescribing, and why maintaining weight loss often requires something deeper than motivation: a shift in identity.
Free course: Improve your metabolic health Get our free email course on how glucose, nutrition, exercise, sleep, and measurement can help you build habits that support better energy and long-term health: https://levels.link/wnl
🎙️ About the Guest: Dr. Robert Kushner is Professor Emeritus of Medicine and Medical Education at Northwestern University Feinberg School of Medicine and one of the pioneers of modern obesity medicine. He is a past president of The Obesity Society, founder and former chair of the American Board of Obesity Medicine, and a lead investigator on the landmark STEP clinical trials that helped establish semaglutide as a treatment for obesity.
📍What Dr. Robert Kushner & Mike Haney discussed: 2:06 — Why obesity is more than willpower 4:34 — The benefits and drawbacks of calling obesity a disease6:27 — Clinical vs. preclinical obesity 17:36 — What obesity medicine misunderstood about weight regain 18:44 — “Fight biology with biology” 25:07 — Why weight maintenance is a different challenge than weight loss 26:49 — The identity shift that helps people keep weight off 27:52 — How GLP-1 drugs actually work 31:09 — Why some people experience constant food noise 34:09 — Why GLP-1s treat obesity but don’t cure it 42:17 — The STEP and SELECT trials 44:15 — Who should consider GLP-1 medications? 45:44 — Why obesity treatment is more than an online prescription 50:44 — What happens after you stop taking GLP-1s?
🔗 Helpful Links: Watch the conversation: https://youtu.be/qdssFUAWVck Dr. Robert Kushner: https://drrobertkushner.com/about/ Northwestern Faculty Profile: https://www.feinberg.northwestern.edu/faculty-profiles/az/profile.html?xid=11686 STEP Trial: https://www.nejm.org/doi/full/10.1056/NEJMoa2032183 SELECT Trial: https://www.nejm.org/doi/full/10.1056/NEJMoa2307563
👋 Who we are: Levels helps you understand your metabolic health with personalized data, expert guidance, and tools that connect your daily choices to measurable changes in your body. Our goal is to help you make better decisions about food, exercise, sleep, and long-term health.
Look for new shows every month on A Whole New Level, where we have in-depth conversations with thought leaders about metabolic health.
More from LEVELS – A Whole New Level
Heart disease is the leading cause of death, but it’s also one of the most preventable. Decades of research have established a strong causal role for LDL and other ApoB-containing particles in atherosclerosis, and we now have multiple proven ways to lower them. The harder question is how to turn that evidence into a decision for an individual person. Mike Haney talks with Johns Hopkins cardiologist Dr. Seth Martin, a co-author of the new 2026 dyslipidemia guidelines, about what the latest evidence says we should actually measure and act on. The throughline is pragmatic: lower exposure to atherogenic particles earlier and for longer, use additional tests when they can change a decision, and distinguish interesting new measurements from ones that have actually been shown to improve outcomes.
Most of NextLevel starts with a measurement problem: we can see more biology than ever, but we still have to figure out what to do with it. Bioelectronic medicine flips that sequence. We already know how to send electrical signals into the nervous system to change biology, including an FDA-approved vagus nerve treatment for rheumatoid arthritis, even though we still can’t map or read most of the individual nerve fibers carrying those signals.
Most health decisions happen before the science is settled. A study points one way, another points somewhere else, experts disagree about what matters, and even strong population-level evidence may not tell you what will happen to you.
Most medical imaging happens after a symptom, injury, or abnormal test gives a clinician a reason to look. But what changes if imaging becomes a more routine measurement, creating a record of the body before something goes wrong? In this episode of Next Level, Mike Haney talks with Dr. Daniel Durand, chief medical officer at Prenuvo, about whole-body MRI as a test case for a broader shift from episodic medicine toward longitudinal health data. Whole-body MRI is controversial, and Durand is clearly an advocate. The conversation takes the skepticism seriously, then asks a larger question: as measurement gets cheaper, more frequent, and increasingly visible to patients themselves, how should medicine decide what is worth knowing?
Alcohol has spent the last 40 years bouncing between two health narratives: a little is good for your heart, or any amount is dangerous. The science doesn’t really support either slogan. Dr. Tim Naimi has spent decades studying the health effects of alcohol and, just as importantly, why the research is so difficult to interpret. His read of the evidence is less dramatic but more useful: there’s no good reason to start drinking for your health, very low intake may carry little measurable added risk, and risk rises as consumption does. Understanding why earlier studies made moderate drinking look protective helps explain a lot of the whiplashing headlines.